Peter Paschka
Overview
Explore the profile of Peter Paschka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
7726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klank D, Loffler C, Friedrich J, Hoffmann M, Paschka P, Bergner R
Biomedicines
. 2024 May;
12(5).
PMID: 38790994
Kidney involvement with resulting kidney failure leads to increased mortality in patients with multiple myeloma (MM). Cast nephropathy (CN), in particular, if left untreated, quickly leads to kidney failure requiring...
2.
Heudobler D, Luke F, Hahn J, Grube M, Schlosser P, Kremers S, et al.
Haematologica
. 2023 Oct;
109(4):1274-1278.
PMID: 37881883
No abstract available.
3.
Dohner H, Weber D, Krzykalla J, Fiedler W, Kuhn M, Schroeder T, et al.
Lancet Haematol
. 2023 May;
10(7):e495-e509.
PMID: 37187198
Background: Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the...
4.
Gaidzik V, Paschka P, Schlenk R, Weber D, Frohling S, Kramer A, et al.
Hemasphere
. 2023 Apr;
7(5):e877.
PMID: 37101762
No abstract available.
5.
Klank D, Claus B, Bergner R, Paschka P
Microorganisms
. 2022 Dec;
10(12).
PMID: 36557743
The medical care of immunocompromised patients with COVID-19 infection causes major hurdles in the management of these patients in clinical practice. However, poor responses to vaccinations in patients with oncological...
6.
Dohner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, et al.
Blood Adv
. 2022 Apr;
6(18):5345-5355.
PMID: 35486475
We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year...
7.
Klank D, Hoffmann M, Claus B, Zinke F, Bergner R, Paschka P
Hemasphere
. 2021 Dec;
5(11):e651.
PMID: 34901756
No abstract available.
8.
Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik V, Schlenk R, Paschka P, et al.
Haematologica
. 2021 May;
106(11):2986-2989.
PMID: 34047179
No abstract available.
9.
Heuser M, Heida B, Buttner K, Wienecke C, Teich K, Funke C, et al.
Blood Adv
. 2021 Apr;
5(9):2294-2304.
PMID: 33929500
Next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring in patients with acute myeloid leukemia (AML) is widely applicable and prognostic prior to allogeneic hematopoietic cell transplantation (alloHCT). We evaluated the...
10.
Bergner R, Hoffmann M, Uppenkamp M, Paschka P, Klank D
Eur J Haematol
. 2021 Mar;
106(6):836-841.
PMID: 33725381
Background: Cast nephropathy (CN) is associated with a unfavourable outcome in monoclonal light chain (mLC) disease, but also more possible LC-related renal diseases as well as non-LC-related disease can occur....